AU2020378437A1 - Formulations for release-rate modulating films for gastric residence systems - Google Patents

Formulations for release-rate modulating films for gastric residence systems Download PDF

Info

Publication number
AU2020378437A1
AU2020378437A1 AU2020378437A AU2020378437A AU2020378437A1 AU 2020378437 A1 AU2020378437 A1 AU 2020378437A1 AU 2020378437 A AU2020378437 A AU 2020378437A AU 2020378437 A AU2020378437 A AU 2020378437A AU 2020378437 A1 AU2020378437 A1 AU 2020378437A1
Authority
AU
Australia
Prior art keywords
arm
pdl
release rate
pcl
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020378437A
Other languages
English (en)
Inventor
David Altreuter
Estelle BEGUIN
Saumya MOORTHY
Tammy TAI
Alisha Weight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nortiva Bio Inc
Original Assignee
Nortiva Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nortiva Bio Inc filed Critical Nortiva Bio Inc
Publication of AU2020378437A1 publication Critical patent/AU2020378437A1/en
Assigned to Nortiva Bio, Inc. reassignment Nortiva Bio, Inc. Request for Assignment Assignors: LYNDRA THERAPEUTICS, INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020378437A 2019-11-08 2020-11-06 Formulations for release-rate modulating films for gastric residence systems Pending AU2020378437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933313P 2019-11-08 2019-11-08
US62/933,313 2019-11-08
PCT/US2020/059536 WO2021092486A1 (en) 2019-11-08 2020-11-06 Formulations for release-rate modulating films for gastric residence systems

Publications (1)

Publication Number Publication Date
AU2020378437A1 true AU2020378437A1 (en) 2022-06-02

Family

ID=75849585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020378437A Pending AU2020378437A1 (en) 2019-11-08 2020-11-06 Formulations for release-rate modulating films for gastric residence systems

Country Status (7)

Country Link
US (1) US20220387310A1 (https=)
EP (1) EP4054642A4 (https=)
JP (1) JP2022554383A (https=)
CN (1) CN114938634A (https=)
AU (1) AU2020378437A1 (https=)
CA (1) CA3160660A1 (https=)
WO (1) WO2021092486A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060631A (ko) * 2018-10-16 2021-05-26 리써치 트라이앵글 인스티튜트 피하 생분해성 저장소 디바이스
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
MX2021011314A (es) 2019-03-20 2021-12-10 Lyndra Therapeutics Inc Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
JP2022525482A (ja) 2019-03-20 2022-05-16 リンドラ セラピューティクス， インコーポレイティド 胃内滞留剤形用のコーティング
CN116234540A (zh) 2020-07-29 2023-06-06 赛康特集团有限责任公司 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留
CN121360261A (zh) * 2025-12-23 2026-01-20 天津和治友德制药有限公司 一种生物膜基材、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20130273135A1 (en) * 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
US20130017264A1 (en) * 2011-07-15 2013-01-17 Piramal Life Sciences Limited Alginate tube drug delivery system and method therefor
WO2015119653A1 (en) * 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US20170266112A1 (en) * 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2015191922A1 (en) * 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Enteric elastomers
HK1258050A1 (zh) * 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
US11576866B2 (en) * 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP3547974B1 (en) * 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system
US12023406B2 (en) * 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
AU2018337837B2 (en) * 2017-09-20 2024-03-07 Nortiva Bio, Inc. Encapsulation of gastric residence systems
US11684315B2 (en) * 2017-11-28 2023-06-27 Massachusetts Institute Of Technology Gastric resident electronics

Also Published As

Publication number Publication date
CN114938634A (zh) 2022-08-23
JP2022554383A (ja) 2022-12-28
CA3160660A1 (en) 2021-05-14
EP4054642A4 (en) 2024-02-28
EP4054642A1 (en) 2022-09-14
US20220387310A1 (en) 2022-12-08
WO2021092486A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US20220387310A1 (en) Formulations for release-rate modulating films for gastric residence systems
JP7588177B2 (ja) 放出速度調節フィルムを有する胃内滞留システム
US20220387311A1 (en) Gastric residence systems for administration of active agents
US20240423909A1 (en) Materials architecture for gastric residence systems
JP3902229B2 (ja) 結腸デリバリー用の、多腸溶ポリマー被覆物を有する医薬投与形態
US20220409528A1 (en) Gastric residence systems having a filament for improved gastric residence
US11135159B2 (en) Optimized high-dose mesalazine-containing tablet
US20230190941A1 (en) Polymeric linkers for a gastric residence system
EP4719179A2 (en) Manufacturing methods for gastric residence systems
JPWO2021092491A5 (https=)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NORTIVA BIO, INC.

Free format text: FORMER APPLICANT(S): LYNDRA THERAPEUTICS, INC.